Review Article: TL1A Inhibitors in IBD ‐ Mechanistic Rationale and Clinical Evidence
Alimentary Pharmacology & Therapeutics · 2026-06 · 63 (11) · 1458-1473
DOI: 10.1111/apt.70648 ↗At a glance
Übersichtsarbeit in Alimentary Pharmacology & Therapeutics, published online on 2026-04-06. Written by Manjeet Kumar Goyal and 5 co-authors. Institution: Department of Internal Medicine, Cleveland Clinic Akron General, Akron, Ohio, USA. Major MEDLINE topics: Tumor Necrosis Factor Ligand Superfamily Member 15, Inflammatory Bowel Diseases, Receptors, Tumor Necrosis Factor, Member 25. Cited 5 times so far (Crossref); 66 references.
Abstract (original language)
Background
Tumour necrosis factor‐like ligand 1A (TL1A) and its receptor DR3 form a pivotal signalling dyad linking immune activation, epithelial barrier dysfunction and fibrogenesis in inflammatory bowel diseases. (IBD).
Aims
This narrative review summarizes the molecular biology of the TL1A–DR3 axis, its roles in intestinal inflammation, fibrosis, and extraintestinal manifestations, and the emerging therapeutic landscape of TL1A inhibition in IBD.
Methods
Narrative synthesis of preclinical, translational, and clinical literature on TL1A/DR3 in Crohn's disease and ulcerative colitis.
Results
TL1A overexpression drives Crohn's‐like ileitis, barrier disruption, and fibrosis in models; blockade attenuates both inflammation and remodelling. TL1A inhibitors show clinical/endoscopic remission in early‐phase moderate–severe IBD trials (e.g., tulisokibart, duvakitug), with phase 3 programs ongoing.
Conclusion
TL1A–DR3 integrates mucosal immunity with stromal injury, positioning inhibitors as a novel class to overcome IBD therapeutic ceilings by targeting the inflammation‐fibrosis continuum.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Internal Medicine, Cleveland Clinic Akron General, Akron, Ohio, USA.
- Department of Medicine, VMMC and Safdarjung Hospital, New Delhi, India.
- Department of Medicine, Dayanand Medical College and Hospital, Ludhiana, India.
- Clinical Assistant Professor, Division of Gastroenterology, Department of Medicine, Michigan Medicine, Ann Arbor, Michigan, USA.
- Additional Professor of Gastroenterology, Department of Gastroenterology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
- IBD Unit, Department of Gastroenterology, Hull University Teaching Hospitals NHS Trust, Hull, UK.
ORCID profiles: Manjeet Kumar Goyal, Shrinivas Bishu, Vishal Sharma
Cite
APA
Goyal, M. K., Srivastava, H., Sehgal, T., Bishu, S., Sharma, V., & Sebastian, S. (2026). Review Article: TL1A Inhibitors in IBD ‐ Mechanistic Rationale and Clinical Evidence. Alimentary Pharmacology & Therapeutics, 63(11), 1458-1473. https://doi.org/10.1111/apt.70648
Vancouver
Goyal MK, Srivastava H, Sehgal T, Bishu S, Sharma V, Sebastian S. Review Article: TL1A Inhibitors in IBD ‐ Mechanistic Rationale and Clinical Evidence. Alimentary Pharmacology & Therapeutics. 2026;63(11):1458-1473. doi:10.1111/apt.70648
BibTeX
@article{Goyal2026,
author = {Goyal, Manjeet Kumar and Srivastava, Harsh and Sehgal, Tanisha and Bishu, Shrinivas and Sharma, Vishal and Sebastian, Shaji},
title = {Review Article: TL1A Inhibitors in IBD ‐ Mechanistic Rationale and Clinical Evidence},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2026},
volume = {63},
number = {11},
pages = {1458--1473},
doi = {10.1111/apt.70648}
}
EUVIMED